November 16, 2011
Westlaw Journal
On December 7, 2011, The U.S. Supreme Court will hear arguments on the validity of two patents held by Prometheus Laboratories that cover abstract thoughts or processes in the field of biological sciences. The patents involve methods for calibrating the proper dosage of drugs to treat autoimmune diseases, according to filings before the high court. Finnegan partner Denise DeFranco said of the case, “Many patents in the life science space may be impacted by the decision…If the Supreme Court decides that Prometheus’ diagnostic patent claims are not patentable, then patents directed to methods of diagnosing and/or treating disease may be vulnerable to attack."
Award/Ranking
Best Lawyers in Germany Recognizes Dr. Dr. Jochen Herr in Recent Rankings
July 16, 2026
Commentary
Patent Strategy Could Shape Financing, Valuation and Risk in Offshore Energy Projects
June 30, 2026
Award/Ranking
Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings
June 25, 2026
Press Release
BMW Obtains Preliminary Injunction Against Zync; Federal Court Orders Zync to Halt ITC Trade Secret
June 23, 2026
Award/Ranking
Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers
June 22, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.